Ublituximab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Explore 203 assets in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
TG Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04806035CT.gov Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | — | Terminated | — | — | — |
NCT04149821CT.gov Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | — | Terminated | — | — | — |
NCT04624633CT.gov Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | — | Active Not Recruiting | — | — | — |
NCT04016805CT.gov Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | — | Terminated | — | — | — |
NCT03828448CT.gov Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | — | Terminated | — | — | — |
NCT03801525CT.gov Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | — | Terminated | — | — | — |
NCT03671590CT.gov Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | — | Terminated | — | — | — |
NCT03379051CT.gov Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | — | Terminated | — | — | — |
NCT03207256CT.gov Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | — | Terminated | — | — | — |
NCT02793583CT.gov Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | — | Terminated | — | — | — |
Show 9 more trialsShow fewer
NCT02656303CT.gov A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | — | Terminated | — | — | — |
NCT02612311CT.gov Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | — | Terminated | — | — | — |
NCT02535286CT.gov Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | — | Completed | — | — | — |
NCT02301156CT.gov Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | — | Completed | — | — | — |
NCT02013128CT.gov Ublituximab + Ibrutinib in Select B-cell Malignancies | — | Completed | — | — | — |
NCT02006485CT.gov Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | — | Completed | — | — | — |
NCT01744912CT.gov Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | — | Terminated | — | — | — |
NCT01647971CT.gov Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01098188CT.gov LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ublituximab (this asset) | TG Therapeutics, Inc. | P3 | B · 56 |
| Chlorambucil | Ascentage Pharma Group Inc. | P4 | BBB |
| Etoposide | Weill Medical College of Cornell University | P2 | BBB |
| Lisaftoclax | Henan Cancer Hospital | P3 | BBB |
| Prednisone | AstraZeneca | P3 | BBB |
| Irinotecan | IGM Biosciences, Inc. | P2 | BBB |
| Rituximab | M.D. Anderson Cancer Center | P4 | BB |
| Ppsv23 | Region Örebro County | P4 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort
Other indications for Ublituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BB · 66 |
| Marginal Zone Lymphoma | — | P2/3 | B · 57 |
| Follicular Lymphoma | — | P2/3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ublituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ublituximab-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →